Vitamin D is thought to have neuroprotective effects and it is usually lacking in patients with Parkinson disease (PD).
In a study published this month, researchers said they now have clarity into the vitamin D pathway in the brains of patients with Parkinson disease.
Vitamin D is thought to have neuroprotective effects and it is usually lacking in patients with PD. The nerve cell loss in PD is thought to be triggered mainly by the toxic buildup of alpha-synuclein (α-synuclein). Astrocytes, a type of glial cell, are involved in PD in 2 ways: they both add to α-synuclein pathology but also help clear α-synuclein.
Researchers in Italy analyzed vitamin D pathway components CYP27B1, CYP24A1, and 1,25-dihydroxyvitamin D receptor (VDR) in brain tissue obtained from 9 deceased patients with PD and 4 controls without neurodegenerative disease.
Patients with PD numbered 5 men and 4 women aged 71 to 91 at time of death. All had severe α-synuclein-related neurodegeneration. The controls included 3 women and 1 man, all aged 64 to 93.
CYP27B1 astrocytes were found in the brains of PD patients but not controls.
The researchers also found that the level of CYP27B1 expression correlated with clinical aspects of disease. Expression in the frontal cortex white matter was significantly higher in patients with Lewy body pathology, but without white matter alteration or dementia, while patients with PD and white matter alterations and dementia had significantly fewer CYP27B1 positive astrocytes in the cortex, although there was no difference in the total number of filament cells related to neuronal damage.
“We found that the brains of PD patients without dementia have a threefold higher content of CYP27B1 positive astrocytes in the frontal cortex and do not have white matter degeneration, thus suggesting that vitamin D could exert its neuroprotective role through astrocytes,” the researchers wrote.
One limitation of the study is that they could not assess vitamin D levels in the deceased patients or explore their genetic status.
The researchers called the relationship between vitamin D and PD “complex” and called for further studies.
Reference
Mazzetti S, Barichella M, Giampietro F, et al. Astrocytes expressing Vitamin D-activating enzyme identify Parkinson’s disease. CNS Neurosci Ther. Published online February 15, 2022. doi.org/10.1111/cns.13801
Major Study Expands in Hopes to Cure Parkinson Disease
April 19th 2022April is Parkinson’s Disease Awareness month, and on this episode of Managed Care Cast, we take a look at the Parkinson's Progression Markers Initiative (PPMI), a study from the Michael J. Fox Foundation for Parkinson's Research (MJFF). The multicenter, international study aims to end Parkinson disease, which is expected to double worldwide by 2040, to more than 14 million people.
Listen
PD Worsens QOL, Increases Depression in Men More Than Women in the Southeast
February 17th 2023The southeastern areas of the country have worse health outcomes and health-related quality of life (HRQOL) compared with other parts of the United States, with high rates of diabetes, obesity, cancer, and cardiovascular disease.
Read More
An Inside Look at Innovations by MJFF to Assist the Parkinson Community Amid the COVID-19 Pandemic
May 26th 2020On this episode of Managed Care Cast, we speak with Rachel Dolhun, MD, vice president of Medical Communications at The Michael J. Fox Foundation for Parkinson Research, about recent innovations by The Michael J. Fox Foundation to assist patients and families of patients with Parkinson disease in adjusting to this new normal.
Listen